<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3478">27 patients (11 males, 16 females) were included. Mean age was 54.2 ± 13.4 years. The mean APACHE II score was 14.9 ± 4.1. 37.0 % died while on Intensive Care. The underlying diagnosis of respiratory failure included COPD in 14 and severe asthma in 13 patients. The mean length of stay in critical care was 10.9 ± 8.7 days. All patients were intubated on admission and 26 patients (96.3 %) were receiving controlled ventilation. By Day 5, 17 patients were still ventilated, with 10 patients on controlled ventilation, 8 were weaned to ASB, CPAP, or SIMV. Ketamine was given for 3.9 ± 1.9 days. On day 1 of ketamine treatment the Peak Inspiratory Pressure-max was 30.0 ± 3.4 mmHg and PEEP-max was 8.0 ± 3.7 mmHg. 25 patients received intravenous aminophylline (92.6 %), 20 salbutamol (74.1 %) and 22 MgSO4 (81.5 %). The total dose on days 1 to 5 was 73.9 ± 64.9, 130.7 ± 76.7, 127.1 ± 56.4, 101.0 ± 73.8 and 124.7 ± 84.2 mg. pCO2-max decreased from 15.5 ± 6.1 kPa to 8.8 ± 3.5 kPa, lactate-max decreased from 3.5 ± 2.6 mmol/L to 1.6 ± 1.0 mmol/L, whereas pH-min increased from 7.06 ± 0.15 to 7.34 ± 0.11. Abdominal distension was observed in 5 patients and 13 failed to absorb enteral feeds. Delirium requiring treatment with haloperidol was seen in 5 patients. 14 patients (51.9 %) had X-ray changes consistent with infection and 19 patients (70.4 %) had positive microbiology results within the first 7 days of ketamine administration. 2 patients (7.4 %) developed new onset AF and 22 patients (81.5 %) had episodes of tachycardia.</p>
